Molecular Therapy-Oncolytics

Papers
(The H4-Index of Molecular Therapy-Oncolytics is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1238
Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models79
Ferroptosis gene signature in cholangiocarcinoma55
Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence46
esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation44
Metabolic remodeling in tumor-associated macrophages contributing to antitumor activity of cryptotanshinone by regulating TRAF6-ASK1 axis43
Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma38
A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers36
Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML36
Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity33
PROTACs in gastrointestinal cancers33
Cancer stem/progenitor signatures refine the classification of clear cell renal cell carcinoma with stratified prognosis and decreased immunotherapy efficacy33
CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer32
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy32
In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiforme31
Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T30
Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response30
Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity30
A library of cancer testis specific T cell receptors for T cell receptor gene therapy29
Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia29
Replication-incompetent influenza A viruses armed with IFN-γ effectively mediate immune modulation and tumor destruction in mice harboring lung cancer29
Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia28
The role and application of vesicles in triple-negative breast cancer: Opportunities and challenges27
Adding recombinant AAVs to the cancer therapeutics mix26
Radiovirotherapy at twenty26
Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products26
0.10401082038879